Claim 01 · Public issuer identity
Nasdaq: RXRX
The reviewed market record resolves the issuer, exchange and ticker against primary filing or investor evidence.
Public companyPROBABLEBaseline coverage
Recursion Pharmaceuticals, Inc.
COMPANY-RECURSION-001 · observed August 4, 2026
A clinical-stage TechBio company operating an AI-native drug-discovery platform across biology, chemistry and development.
AI nativeData & tooling
Evidence boundary
This baseline is projected from the governed Markets research record. Listing identity, AI-role evidence and market context are available now; products, people, headquarters and relationship entities require separate source-level admission.
Location and contact
Where to find Recursion Pharmaceuticals.
Official presence
Business address, phone and investor relations are projected only when explicitly present in the SEC issuer record. Social channels, email and headquarters interpretation require separate first-party review. Official-link discovery observed 2/2 selected pages and auto-admitted 4 canonical channels. Alternate and semantically ambiguous links remain review candidates.
External market projection
RXRX · 30-day price trajectory
External market data remains a dated projection attached to the company—it does not define company identity.
$3.31
latest close
-12.89%
30 days
Observed 2026-08-05T05:33:04.700Z · close prices · USDProvider source
Research thesis
What this company is in the AI economy.
Recursion Pharmaceuticals, Inc. is admitted to the public AI company universe as ai native. The classification describes its observed operating role in the AI economy; it does not convert the issuer into a pure-play AI company or an investment recommendation.
Knowledge-bearing claims
Important assertions stay explainable.
Claim 02 · Primary AI-economy role
AI native
The annual filing identifies the Recursion OS and its integration of proprietary data, machine learning and automated experimentation.
Claim 03 · SEC issuer record
RECURSION PHARMACEUTICALS, INC. · CIK 0001601830
Regulator-recorded issuer identity from the SEC submissions endpoint. It does not establish AI exposure or investment merit.
Products and operating surfaces
Products are independent entities linked to the company. They are not aliases for the organization itself.
Product coverage pending
No product has passed entity identity and source review for this profile yet.
People
Ben Taylor
Chief Financial Officer and President of Recursion UK
Recursion Pharmaceuticals, Inc.'s DEF 14A identifies Ben Taylor as Chief Financial Officer and President of Recursion UK.
Open person profile
David Hallett
Chief Scientific Officer
Recursion Pharmaceuticals, Inc.'s DEF 14A identifies David Hallett as Chief Scientific Officer.
Open person profile
Najat Khan
Chief Executive Officer and President
Recursion Pharmaceuticals, Inc.'s DEF 14A identifies Najat Khan as Chief Executive Officer and President.
Open person profile
Explainable ecosystem
Relationships with a reason.
These are typed, source-backed relationships. Shared categories do not automatically become competitor claims.
0 governed edges
Origin entity
Recursion Pharmaceuticals
AI native
0
edges
0
sources
Relationship coverage pending
No relationship has passed the evidence and scope boundary for this profile yet.
Material change over time
Financial report·
10-K annual filing observed
The latest annual filing available in the current SEC projection was filed on 2026-02-25.
Public market projection
Nasdaq: RXRX
The Markets profile contains price, filing and financial projections. This Company Intelligence page preserves entity identity, evidence boundaries and future enrichment state.
Evidence chain
First-party sources prove attribution: what the organization reports about itself. They do not automatically prove every outcome or interpretation.
Official company statement · E2
Recursion Pharmaceuticals, Inc. official website
SRC-RECURSION-OFFICIAL-WEBSITE · Recursion Pharmaceuticals, Inc.
Official filing or investor report · E2
Recursion Pharmaceuticals, Inc. SEC submissions record
SRC-RECURSION-SEC-SUBMISSIONS · U.S. Securities and Exchange Commission
Official filing or investor report · E3
Recursion 2025 Form 10-K
SRC-REAL-019-A · Recursion Pharmaceuticals, Inc.
Official filing or investor report · E3
Recursion Full Year 2025 Results
SRC-REAL-019-B · Recursion Pharmaceuticals, Inc.
Official product material · E2
Technology
SRC-DISC-RECURSION-F61413802DD8 · Recursion Pharmaceuticals, Inc.
Official filing or investor report · E3 · 2026-04-30
Recursion Pharmaceuticals, Inc. DEF 14A filed 2026-04-30
SRC-SEC-LEAD-RECURSION-183026000065 · U.S. Securities and Exchange Commission
Official leadership record · E2
Meet our Team | Recursion
SRC-IRMEDIA-RECURSION-1D58441EA09B · Recursion Pharmaceuticals, Inc.
Related profiles
Continue through the AI economy.
This projection is based only on shared category and declared operating roles. It is not a competitor or investment claim.
